Plain-English translation of NCT05296304 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new combination treatment for mycosis fungoides, a type of skin lymphoma (blood cancer that starts in the skin). The trial combines a medication called —a form of vitamin A that helps fight cancer cells—with a specialized radiation therapy that treats the entire skin surface with very low doses of radiation. Researchers believe that giving these two treatments at the same time may work better together than either treatment alone.
Mycosis fungoides can be difficult to treat, and doctors are looking for better ways to help patients. This trial explores whether combining this medication with radiation therapy might be more powerful at shrinking tumors and clearing the cancer from the skin.
You likely qualify if…
You likely don't qualify if…
You will start taking the medication by mouth at a low dose, which will gradually increase over two weeks. About three weeks after starting, you will receive your first cycle of radiation therapy, which involves two short treatment sessions on consecutive days—the radiation only reaches your skin and doesn't go deeper into your body. Your doctors will check how you're doing about one month later and again at two months. If your skin hasn't improved enough, you may receive additional radiation cycles (up to 6 total) until you see a good response or until your doctors decide to stop treatment.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States